AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Stereotaxis Inc. (STXS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

2.29

0.02 (0.88%)

At close: Feb 20, 2025, 3:59 PM

2.29

-0.22%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	2.28
Market Cap	194.45M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.27
PE Ratio (ttm)	-8.5
Forward PE	n/a
Analyst	Strong Buy

Ask	2.3
Volume	579,498
Avg. Volume (20D)	415,901
Open	2.27
Previous Close	2.27
Day's Range	2.18 - 2.62
52-Week Range	1.66 - 3.29
Beta	undefined

About STXS

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the...

[Show more]

Industry Medical - Instruments & Supplies

Sector Healthcare

IPO Date Aug 12, 2004

Employees 122

Stock Exchange AMEX

Ticker Symbol STXS

Website https://www.stereotaxis.com

Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for STXS stock is "Strong Buy." The 12-month stock price forecast is $4.5, which is an increase of 96.08% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Stereotaxis Inc. is scheduled to release its earnings on Mar 3, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 weeks ago

+5.48%

Stereotaxis shares are trading higher after the co... Unlock content with Pro Subscription

6 months ago

-3.74%

Stereotaxis shares are trading higher after the company achieved CE Mark approval in Europe and submitted a 510(k) application to the FDA for its GenesisX Robotic System.

News

6 days ago · seekingalpha.com

Stock Market Sleeps On Stereotaxis MAGiC CE Mark

Stereotaxis' MAGiC catheter received CE Mark approval in Europe, enabling the company to earn an additional $3k per procedure with +80% gross margins. FDA approval of MAGiC is expected by September. T...

2 weeks ago · zacks.com

STXS Stock Gains Following the First Order for its GenesisX

Stereotaxis receives its first order for the next-generation robotic system, GenesisX. The company expects a full commercial launch in the coming months.

2 months ago · zacks.com

STXS Stock Up Post NMPA Nod for Cardiovascular Care With Magbot

Stereotaxis' latest regulatory approval in China is likely to offer a minimally-invasive treatment solution for complex arrhythmia patients and improve global cardiovascular care.

2 months ago · seekingalpha.com

Stereotaxis To Drive Transformational Growth Via Full Ecosystem Launch In 2025

MAGiC is set to receive the CE Mark by early 2025. Tenders will be completed by Q2 or Q3 2025; the FDA approval timeline is similar. The APT acquisition allowed Stereotaxis to complete the manufacturi...

2 months ago · zacks.com

STXS Stock Up Following the NMPA Clearance of Its Genesis RMN System

Stereotaxis, in collaboration with MicroPort EP, announces the receipt of NMPA approval for its Genesis RMN System.